abstract: A technique developed in @entity1527 biochemical studies was successfully used to fractionate @entity14427 ( @entity14427 ) amazonensis promastigotes. Ultrastructural analyses revealed a @entity231 ( @entity231 ) associated to subpellicular microtubules, a ribosomal-rich microsomal fraction (MicF), and a flagellar fraction (FF) free of associated membrane. All fractions proved to be immunogenic through delayed type @entity56 reaction assays. Therefore, a protocol was designed to test whether these fractions could elicit a protective response in @entity19 infected by L. (L), amazonensis. The protocol consisted of a BCG injection (as cellular immunity inducer), followed by @entity786 (once its cytotoxic effect is over, this immunosuppressor can increase the number of circulating leukocytes), then an injection with one of the fractions followed by a challenge. When compared to infected control animals, @entity19 injected with any of the fractions presented a smaller footpad swelling, especially those injected with MicF or FF. Macroscopically, immunized @entity19 under modulation by BCG presented no swelling. Histopathological studies performed on day 120 revealed fewer amastigotes and more intense inflammation in lesions of MicF and FF injected @entity19 . Animals injected with @entity231 presented an intermediate pattern. Parasite quantification corroborated these results. The results show that all fractions are potent immunostimulators, but MicF and FF have the strongest protective ability.

title: Experimental XXXX (L.) amazonensis leishmaniasis: characterization and immunogenicity of subcellular fractions.

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['membrane fraction', 'MF']

entities_list: @entity1527 :: ('5693', 'Species') :: ['Trypanosoma cruzi']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity14427 :: ('MESH:C536652', 'Disease') :: ['Leishmania']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity']

answer: @entity14427 :: (MESH:C536652,Disease) :: ['Leishmania']


abstract: Heparin and other polysulfated glycosaminoglycans (GAGPS) can evoke an immune response when complexed to the surface of platelets in vivo. We have previously reported on the detection and characteristics of such antibodies leading to @entity882 . Here we report data concerning the biochemical characterization of the heparin-/GAGPS-binding site on @entity1 thrombocytes. By means of heparin affinity chromatography, GAGPS chromatography and subsequent 'Western blotting' of specifically eluted proteins we were able to detect two proteins of apparent molecular mass of 207 and 170 kilodaltons, which could be reduced to 57 and 142 kilodaltons, respectively. The 170-kilodalton glycoprotein was stained by the @entity1735 specific PAS-reagent and by surface labeling with 3H. The second molecule binding to heparin (GAGPS)-Sepharose was detected by platelet surface labeling with 125I, protein-specific staining Coomassie brilliant blue and PAS staining. Binding studies using enzyme-labeling techniques with five monoclonal antibodies (MCA) against platelet surface proteins @entity14243 , @entity1427 /IIIa complex, @entity1428 and CRI (C3b receptor) revealed specific interaction of the 170-kilodalton heparin-binding glycoprotein with an MCA to @entity14243 , suggesting identity or immunological cross-reactivity of these two moieties. No specific reactions were observed between the 207-kilodalton glycoprotein and any of the MCA tested. For further evaluation of the antigenicity of separated platelet proteins, an ELISA in microtiter plates was developed, and a cellular sandwich ELISA for serological detection of antibodies against whole native thrombocytes or GAGPS-derivatized proteins was set up.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Identification of binding site for heparin and other polysulfated glycosaminoglycans on XXXX thrombocytes.

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: Primary angioplasty (direct angioplasty without antecedent thrombolytic therapy) has remained an exclusive and consistent method of @entity1188 intervention at our institution over the past 13 years. A total of 1,000 consecutive @entity1 were prospectively enrolled in our primary angioplasty database. Of @entity1 presenting to our group with an @entity583 , 96% of those eligible received immediate angioplasty. @entity1455 was noted in 79 @entity1 (7.9%). The mean time from @entity158 onset to reperfusion was 5.4 +/- 4.0 hours. @entity1188 was accomplished in 94% of @entity1 . Recanalization rates were similar among the 3 native epicardial coronary systems but were lower in bypass grafts (86%; p < 0.0001). Overall in-hospital mortality was 7.8%; mortality with @entity1455 was 44%. Global ejection fraction increased from 49.7% preangioplasty to 57.4% at the time of dismissal. The amount of @entity296 was highly dependent on the size of the initial @entity1188 (the largest @entity1188 benefiting the most). @entity1 reperfused in < 2 hours experienced a very low mortality (4%) and impressive @entity296 . Complications included @entity64 in 0.5%, significant @entity548 in 2.8%, and early reocclusion of the @entity1188 vessel in 13%. Primary angioplasty is broadly applicable to @entity1 presenting with @entity583 and results in a very high rate of @entity1188 vessel recanalization, with a mortality rate of 7.8%. This strategy may be uniquely effective in @entity1 presenting with @entity1455 , large @entity1188 , contraindications to thrombolytic therapy, and prior bypass surgery.

title: Primary angioplasty for @entity583 in 1,000 consecutive XXXX . Results in an unselected population and high-risk subgroups.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial salvage']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarctions', 'Infarct-vessel recanalization', 'infarct', 'infarction']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['acute myocardial infarction']

entities_list: @entity1455 :: ('MESH:D012770', 'Disease') :: ['Cardiogenic shock', 'cardiogenic shock']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: Citrus Huanglongbing (HLB) is the most destructive citrus disease worldwide. HLB is associated with three species of the phloem-limited, gram-negative, fastidious a-proteobacteria: @entity30224 (Las), Ca. @entity60667 (Lam), and @entity9495 . L. africanus (Laf) with Las being the most widespread species. Las has not been cultured in artificial media, which has greatly hampered our efforts to understand its virulence mechanisms. Las contains a complete Sec-translocon, which has been suggested to transport Las proteins including virulence factors into the extracytoplasmic milieu. In this study, we characterized the Sec-translocon dependent, signal peptide containing extracytoplasmic proteins of Las. A total of 166 proteins of Las-psy62 strain were predicted to contain signal peptides targeting them out of the cell cytoplasm via the Sec-translocon using LipoP, SigalP 3.0, SignalP 4.1, and Phobius. We also predicated SP containing extracytoplasmic proteins for Las-gxpsy and Las-Ishi-1, Lam, Laf, Ca. @entity16828 (Lso), and @entity60668 (Lcr). For experimental validation of the predicted extracytoplasmic proteins, @entity526 based alkaline phosphatase (PhoA) gene fusion assays were conducted. A total of 86 out of the 166 predicted Las proteins were experimentally validated to contain signal peptides. Additionally, Las-psy62 lepB ( @entity60669 ), the gene encodes signal peptidase I, was able to partially complement the amber mutant of lepB of @entity526 . This work will contribute to the identification of Sec-translocon dependent effector proteins of Las, which might be involved in virulence of Las.

title: SEC-Translocon Dependent Extracytoplasmic Proteins of XXXX .

entities_list: @entity30224 :: ('34021', 'Species') :: ['Candidatus Liberibacter asiaticus']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity30224 :: (34021,Species) :: ['Candidatus Liberibacter asiaticus']


abstract: Clinical evidence suggest @entity854 in @entity308 ( @entity308 ) while treatment with anti- @entity716 drugs affects astroglial functions. Astroglial cells are involved in pH homeostasis of the brain by transporting protons (through @entity1372 -proton transporter 1, @entity32815 , @entity2227 transporters @entity59521 and proton- @entity880 co-transporter @entity3195 ) and @entity3157 (through the @entity1372 - @entity3157 co-transporter NBC or the @entity2865 - @entity3157 exchanger AE). Here we show that chronic treatment with @entity905 increases astroglial pH i by stimulating @entity32815 -mediated proton extrusion. At a clinically relevant concentration of 1  M, @entity905 significantly increased astroglial pH i from 7.05 to 7.34 after 3 weeks and from 7.18 to 7.58 after 4 weeks of drug treatment. Stimulation of @entity32815 is a result of transporter phosphorylation mediated by several intracellular signaling cascades that include MAPK/ @entity1366 , @entity10412 / @entity584 and @entity34562 ( @entity34562 ). @entity905 stimulated phosphorylation of @entity1366 , @entity584 and @entity34562 in a concentration dependent manner. Positive crosstalk exists between two signal pathways, MAPK/ @entity1366 and @entity10412 / @entity584 activated by @entity905 since @entity1366 phosphrylation could be abolished by inhibitors of @entity10412 , @entity2306 and @entity584 , @entity25453 , and @entity584 phosphorylation by inhibitor of MAPK, @entity5732 . As a result, @entity34562 phosphorylation was not only inhibited by @entity5732 but also by inhibitor of @entity2306 . The @entity32815 phoshorylation resulted in stimulation of @entity32815 activity as revealed by the @entity8777 -prepulse technique; the increase of @entity32815 activity was dependent on @entity905 concentration, and could be inhibited by both @entity5732 and @entity2306 . Our findings suggest that regulation of astrocytic pH i and brain pH may be one of the mechanisms underlying @entity905 action.

title: XXXX induces alkalinization of astroglial cytosol through stimulation of @entity1372 -hydrogen exchanger 1: dissection of intracellular signaling pathways.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['major depression', 'MD']

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

entities_list: @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine', 'Fluoxetine']

entities_list: @entity3157 :: ('CHEBI:17544', 'Chemical') :: ['bicarbonate']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['astrocytic abnormality']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychotic']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity2865 :: ('CHEBI:17996', 'Chemical') :: ['chloride']

entities_list: @entity34562 :: ('6196', 'Gene') :: ['RSK', 'ribosomal S6 kinase']

entities_list: @entity25453 :: ('MESH:C023764', 'Chemical') :: ['triciribine']

answer: @entity905 :: (MESH:D005473,Chemical) :: ['Fluoxetine']


abstract: BACKGROUND: @entity1209 is commonly associated with adverse consequences and hamper the postoperative recovery in spite of the availability of many antiemetic drugs and regimens for its prevention. The study was aimed to compare the prophylactic effects of intravenously administered @entity7274 , @entity3974 , and @entity10442 on prevention of @entity1209 after general anesthesia. MATERIALS AND METHODS: This prospective, double-blind study, comprised 120 adult consented @entity1 of ASA grade I and II of either gender, was carried out after approval of Institutional Ethical Committee. @entity1 were randomized into three equal groups of 40 @entity1 each in double-blind manner. Group P received inj. @entity7274 (0.075 mg), group O received inj. @entity3974 (4 mg), and group G received inj. @entity10442 (2 mg) intravenously five minutes before induction of anesthesia. The need for rescue antiemetic, episode of @entity1209 , and side effects were observed for 12 hours in the post-anesthesia care unit. At the end of study, results were compiled and statistical analysis was done by using ANOVA, Chi-square test, and Kruskal Wallis Test. Value of P < 0.05 was considered significant. RESULTS: The incidence of @entity390 and @entity391 was maximal during the first four hours postoperatively. The complete control of @entity1209 for first 12 hours was achieved in 30% @entity1 of @entity3974 group, 55% @entity1 of @entity10442 group, and 90% @entity1 of @entity7274 group. Safety profile was more with @entity7274 . CONCLUSION: @entity7274 was comparatively highly effective to prevent the PONV after anesthesia due to its prolonged duration of action than @entity3974 and @entity10442 .

title: @entity7274 , XXXX , and @entity10442 for antiemetic prophylaxis of @entity1209 - A comparative evaluation.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3974 :: ('MESH:D017294', 'Chemical') :: ['ondansetron']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity10442 :: ('MESH:D017829', 'Chemical') :: ['granisetron']

entities_list: @entity7274 :: ('MESH:C083418', 'Chemical') :: ['palonosetron', 'Palonosetron']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['Postoperative nausea and vomiting', 'postoperative nausea and vomiting']

answer: @entity3974 :: (MESH:D017294,Chemical) :: ['Ondansetron']


abstract: @entity392 ( @entity392 ) evoked by clicks and tone bursts (TBs) were measured using a minor modification of the 1987 Bray and Kemp system in normal and @entity393 ears with high-frequency @entity1274 . Sixty ears of 60 subjects were tested. The average behavioral hearing threshold of 20 normally hearing ears was measured for the different "nonlinear" stimulus groups and defined as 0 dBnHL. Emissions were recorded in another 20 normally hearing ears and in 20 ears with steep high-frequency @entity1274 above 2kHz. An unfiltered click of 80 microseconds duration and TBs at frequencies of 0.5, 1, 2, 3, 4, 5, and 6 kHz served as stimuli. The ears with @entity2198 were clearly distinguished from the normal ears in that emission energy decreased with higher frequency stimuli above 2 kHz. The mean slopes of the response-growth functions were significantly higher at lower audiometric thresholds. The normal ears showed a slope of 0.21-0.35 dB/dBnHL above 2 kHz while the slope of the pathological ears was 0.04-0.13 dB/dBnHL. These differences in TBOAEs could possibly be used clinically to carry out hearing tests that are more frequency-specific than those measuring solely click-evoked @entity392 . Pathological ears had emissions in the lower frequency range, where they had a normal audiometric threshold. However, these emissions had significantly far lower amplitudes at frequencies around 0.5 and 1 kHz when compared to normal ears. This reduced emission energy may indicate a cochlear impairment of the pathological ears in frequency ranges where they still had normal audiometric thresholds.

title: Click- and tone-burst-evoked otoacoustic emissions in normally hearing ears and in ears with high-frequency XXXX .

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['sensorineural hearing loss']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing-impaired']

entities_list: @entity392 :: ('MESH:D014012', 'Disease') :: ['Otoacoustic emissions', 'OAEs']

entities_list: @entity2198 :: ('MESH:D006316', 'Disease') :: ['high-frequency hearing loss']

answer: @entity1274 :: (MESH:D006319,Disease) :: ['sensorineural hearing loss']


abstract: BACKGROUND: Intake of @entity6398 and @entity3978 -rich fruit extracts has been shown to reduce markers of @entity32 , @entity409 that result from the consumption of a @entity1386 ( @entity1386 ) diet. OBJECTIVE: The objective of this study was to determine whether @entity19 fed @entity3978 -rich @entity18080 peel extract (AE), cherry extract (CE), and @entity3092 , a phytochemical abundant in fruits including @entity18080 and cherries, would modulate the harmful effects of adiposity on blood @entity413 regulation, endocrine concentrations, and hepatic metabolism in @entity1386 -fed C57BL/6J male @entity19 . METHODS: Groups of 8-wk-old @entity19 (n = 8 each) were fed 5 diets for 10 wk, including low-fat (LF; 10% of total energy) and @entity1386 (60% of total energy) control diets and 3 @entity1386 diets containing @entity3978 -rich AE, CE, and @entity3092 (0.2% wt:wt). Also, an in vitro study used HepG2 cells exposed to @entity3092 (0-100  mol/L) to determine whether intracellular lipid accumulation could be modulated by this phytochemical. RESULTS: @entity19 fed the @entity1386 control diet consumed 36% more energy, gained 14 g more body weight, and had    50% elevated blood @entity413 concentrations (all P < 0.05) than did LF-fed @entity19 . @entity19 fed @entity1386 diets containing AE, CE, or @entity3092 became as @entity28 as @entity1386 -fed @entity19 , but had significantly lower blood @entity413 concentrations after food deprivation (-36%, -22%, -22%, respectively; P < 0.05). Concentrations of serum @entity24759 were reduced 29% in @entity3092 -fed @entity19 compared with @entity1386 -fed controls (P < 0.05). A qualitative evaluation of liver tissue sections suggested that fruit phytochemicals may reduce hepatic lipid accumulation. A quantitative analysis of lipid accumulation in HepG2 cells demonstrated a dose-dependent decrease in lipid content in cells treated with 0-100  mol @entity3092 /L (P < 0.05). CONCLUSIONS: In @entity19 , consumption of AE, CE, or @entity3092 appears to modulate some of the harmful effects associated with the consumption of an obesogenic @entity1386 diet. Furthermore, in a cell culture model, @entity3092 was shown to reduce intracellular lipid accumulation in a dose-dependent fashion.

title: Consumption of @entity3092 and @entity3092 -Containing @entity18080 and Cherry Extracts Affects Blood XXXX Concentration, Hepatic Metabolism, and Gene Expression Patterns in Obese C57BL/6J High Fat-Fed @entity19 .

entities_list: @entity3978 :: ('CHEBI:26195', 'Chemical') :: ['polyphenol']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['diabetes, and hepatic complications']

entities_list: @entity3092 :: ('MESH:D011794', 'Chemical') :: ['quercetin']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity6398 :: ('MESH:D059808', 'Chemical') :: ['polyphenols']

answer: @entity413 :: (MESH:D005947,Chemical) :: ['Glucose']


abstract: AIM: This cross-sectional study examined whether @entity73 are associated with the level of responsibility for life tasks for @entity1 and adolescents with @entity72 ( @entity72 ). METHOD: Parents of 263 @entity1 and adolescents with @entity72 (215 males; 48 females; mean age 12y 6mo [SD 4y 6mo], range 3-21y) completed an online survey that included the Pediatric Evaluation of Disability Inventory-Computer Adaptive Test - Autism Spectrum Disorders (PEDI-CAT-ASD) Daily Activities, Social/Cognitive, and Responsibility domains, a demographic questionnaire, and the Social Communication Questionnaire (SCQ) Current. The International Classification of Functioning, Disability and Health Framework guided the selection of model variables. We used hierarchical multiple regression to examine the relationship between @entity73 predictor variables and the outcome variable, Responsibility. Age was entered in step 1 to control for the impact of development. SCQ Current, IQ, and remaining PEDI-CAT-ASD domains were then entered in step 2. RESULTS: After controlling for age, the model showed that step 2 predictor variables representing both @entity73 improved the model (p<0.001). All variables except the SCQ score were significant predictors of Responsibility. The variance explained by the Daily Activities (2.7%) and Social/Cognitive (4.8%) domain scores was greater than IQ (0.3%). INTERPRETATION: The functional skills of Daily Activities and Social/Cognitive domains were more strongly associated with the management of life tasks than impairments after controlling for age.

title: Association between impairment, function, and daily life task management in XXXX and adolescents with autism.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impairment and functional skill', 'impairments and functional skill', 'impairments or functional skills']

entities_list: @entity72 :: ('MESH:D002659', 'Disease') :: ['ASDs', 'autism spectrum disorders']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: @entity1 genome sequencing has transformed our understanding of genomic variation and its relevance to health and disease, and is now starting to enter clinical practice for the diagnosis of @entity395 . The question of whether and how some categories of genomic findings should be shared with individual research @entity1 is currently a topic of international debate, and development of robust analytical workflows to identify and communicate clinically relevant variants is paramount. METHODS: The @entity245 ( @entity245 ) study has developed a UK-wide @entity1 recruitment network involving over 180 clinicians across all 24 regional genetics services, and has performed genome-wide microarray and whole exome sequencing on @entity1 with undiagnosed @entity245 and their parents. After data analysis, pertinent genomic variants were returned to individual research @entity1 via their local clinical genetics team. FINDINGS: Around 80,000 genomic variants were identified from exome sequencing and microarray analysis in each individual, of which on average 400 were rare and predicted to be protein altering. By focusing only on de novo and segregating variants in known @entity245 genes, we achieved a diagnostic yield of 27% among 1133 previously investigated yet undiagnosed @entity1 with @entity245 , whilst minimising incidental findings. In families with developmentally normal parents, whole exome sequencing of the @entity1 and both parents resulted in a 10-fold reduction in the number of potential causal variants that needed clinical evaluation compared to sequencing only the @entity1 . Most diagnostic variants identified in known genes were novel and not present in current databases of known disease variation. INTERPRETATION: Implementation of a robust translational genomics workflow is achievable within a large-scale rare disease research study to allow feedback of potentially diagnostic findings to clinicians and research @entity1 . Systematic recording of relevant clinical data, curation of a gene-phenotype knowledge base, and development of clinical decision support software are needed in addition to automated exclusion of almost all variants, which is crucial for scalable prioritisation and review of possible diagnostic variants. However, the resource requirements of development and maintenance of a clinical reporting system within a research setting are substantial. FUNDING: Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome Trust and the UK Department of Health.

title: Genetic diagnosis of @entity245 in the XXXX study: a scalable analysis of genome-wide research data.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'child', 'children', 'patient', 'Human']

entities_list: @entity395 :: ('MESH:D035583', 'Disease') :: ['rare diseases']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['Deciphering Developmental Disorders', 'DDD', 'developmental disorders', 'developmental disorder']

answer: @entity245 :: (MESH:D002658,Disease) :: ['DDD']


abstract: BACKGROUND: Little is known about diet quality with a reduced-energy, low-fat, partial meal replacement plan, especially in individuals with @entity164 2 @entity6 . The Action for Health in @entity6 (Look AHEAD) trial implemented a partial meal replacement plan in the Intensive Lifestyle Intervention. OBJECTIVE: To compare dietary intake and percent meeting fat-related and food group dietary recommendations in Intensive Lifestyle Intervention and @entity6 Support and Education groups at 12 months. DESIGN: A randomized controlled trial comparing Intensive Lifestyle Intervention with @entity6 Support and Education at 0 and 12 months. @entity1 /SETTING: From 16 US sites, the first 50% of @entity1 (aged 45 to 76 years, overweight or @entity28 , with @entity164 2 @entity6 ) were invited to complete dietary assessments. Complete 0- and 12-month dietary assessments (collected between 2001 and 2004) were available for 2,397 @entity1 (46.6% of total @entity1 ), with 1,186 randomized to @entity6 Support and Education group and 1,211 randomized to Intensive Lifestyle Intervention group. MAIN OUTCOME MEASURES: A food frequency questionnaire assessed intake: energy; percent energy from protein, fat, @entity1735 , @entity1474 , and saturated fats; @entity15018 ; @entity165 ; fiber; weekly meal replacements; and daily servings from food groups from the Food Guide Pyramid. STATISTICAL ANALYSES PERFORMED: Mixed-factor analyses of covariance, using Proc MIXED with a repeated statement, with age, sex, race/ethnicity, education, and income controlled. Unadjusted      tests compared percent meeting fat-related and food group recommendations at 12 months. RESULTS: At 12 months, Intensive Lifestyle Intervention @entity1 had a significantly lower fat and @entity165 intake and greater fiber intake than @entity6 Support and Education @entity1 . Intensive Lifestyle Intervention @entity1 consumed more servings per day of fruits; vegetables; and milk, yogurt, and cheese; and fewer servings per day of fats, oils, and sweets than @entity6 Support and Education @entity1 . A greater percentage of Intensive Lifestyle Intervention @entity1 than @entity6 Support and Education @entity1 met fat-related and most food group recommendations. Within Intensive Lifestyle Intervention, a greater percentage of @entity1 consuming two or more meal replacements per day than @entity1 consuming less than one meal replacement per day met most fat-related and food group recommendations. CONCLUSIONS: The partial meal replacement plan consumed by Intensive Lifestyle Intervention @entity1 was related to superior diet quality.

title: Partial Meal Replacement Plan and Quality of the Diet at 1 Year: Action for Health in XXXX (Look AHEAD) Trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'PARTICIPANTS']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity1474 :: ('MESH:D005231', 'Chemical') :: ['polyunsaturated fatty acids']

entities_list: @entity15018 :: ('MESH:D044242', 'Chemical') :: ['trans-fatty acids']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity6 :: (MESH:D003920,Disease) :: ['Diabetes']


abstract: After monotherapy with @entity136 in low dose in long infusion, promising results in a variety of advanced chemoresistant @entity5 have been reported. In a previous phase I trial on heavily pre-treated @entity1 , maximum tolerated dose (MTD) of @entity136 in a 6 h infusion was 250 mg/m. The objective of our phase I-II trial was to test the combination of @entity136 in a 6-h infusion and @entity900 in the treatment of advanced @entity1149 ( @entity1149 ). Eligible @entity1 were chemonaive, had locally advanced or metastatic @entity1149 , Eastern Oncology Cooperative Oncology Group performance status 0-2 and normal organ function. Treatment consisted of @entity136 in a 6-h infusion on days 1 and 8, and @entity900 at 75 mg/m on day 2 of a 3-week cycle. During phase I of the trial, the dose of @entity136 was escalated from 130 to 170, 210 and 250 mg/m. After establishing dose-limiting @entity137 (DLT) and MTD of the combination, the trial continued as phase II. Altogether, 61 @entity1 were enrolled, of whom 54 had stage IV disease. In phase I of the trial, groups of six, seven, eight and eight @entity1 were treated at the four dose levels of @entity136 . In phase II, the remaining 32 @entity1 all received @entity136 at 250 mg/m. Serious @entity137 included a @entity1 with grade 5 @entity943 and another with grade 4 @entity63 ; four @entity1 had grade 3 @entity417 . Reversible @entity1148 with platelets over 500 was recorded in 32 @entity1 ; 42 @entity1 had grade 2 @entity1665 . In general, tolerance to this treatment was good. One @entity1 had complete response and 27 had partial responses, for a 28 of 61 (46%) response rate. Median progression-free survival, median survival and 1-year survival were 6 months, 9.5 months and 40%, respectively. We conclude that this treatment has an acceptable, yet distinct, @entity137 profile; routine thromboprophylaxis is recommended. In our population of chemonaive @entity1 , no DLT has been encountered. Due to the remarkable response rate, further research is warranted.

title: Phase I-II trial of low-dose XXXX in prolonged infusion and @entity900 for advanced @entity1149 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocytosis']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['cerebrovascular ischemia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmia']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']


abstract: BACKGROUND: Although @entity3079 has been recognized for a long time, whether it is associated with a poorer prognosis in @entity14 @entity1 is still controversial. Many studies put emphasis on @entity3079 containing @entity3558 component >= 50%. Only a few studies have analyzed cases with a @entity3558 component <50%. OBJECTIVES: This study aimed to analyze the prognostic value of different @entity3558 component proportions in @entity1 with @entity5 . MATERIALS AND METHODS: Clinical, pathological and follow-up data of 136 @entity1 with the @entity5 were collected. Every variable was analyzed by univariate analysis, then multivariate analysis and survival analysis were further performed. RESULTS: Univariate analysis showed pathologic T stage, lymphovascular invasion, and histological subtype were statistically significant for DFS. Pathologic T stage was significant for @entity3012 . Histological subtype and lymphovascular invasion were independent prognostic factors in multivariate analysis for DFS, and histological subtype was the only independent prognostic factor for @entity3012 . Survival curves showed the survival time of @entity3079 ( @entity3079 ) was shorter than non- @entity3079 ( @entity420 with a @entity3558 component <50% and without @entity3558 component). CONCLUSIONS: Histological subtype ( @entity5 with different @entity3558 component) was an independent prognostic factor for both DFS and @entity3012 . @entity1 with @entity3079 had a worse prognosis than their non- @entity3079 counterparts with @entity5 .

title: Prognostic Significance of the XXXX Component in @entity5 @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3079 :: ('MESH:D002288', 'Disease') :: ['MUC', 'mucinous adenocarcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'stage III rectal cancer', 'stage III rectal carcinoma']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']

answer: @entity3558 :: (100508689,Gene) :: ['Mucin']


abstract: The purpose of the present retrospective study was to learn the long-term outcome of oral @entity75 , @entity12120 and erythroplakia, with or without surgical intervention and to relate the outcome to factors supposed to be significant for malignant development including clinical type, demarcation, size, site, presence of @entity5115 , smoking and surgery. A total of 269 lesions in 236 @entity1 were included. Ninety-four lesions were surgically removed, 39 lesions (41%) being homogenous and 46 (49%) @entity12120 whereas nine (5%) were erythroplakias. Seventy-three percent of the lesions were associated with @entity286 habits. The mean size of the lesions was 486 mm(2), and 71% of the lesions showed a degree of @entity5115 . After excision the defects were closed primarily by transposition of @entity33 or they were covered by free mucosal or skin grafts. A few defects were left for secondary healing. After surgical treatment the @entity1 were followed (mean 6.8 yrs, range 1.5-18.6 yrs), and new biopsies taken in case of recurrences. One hundred and seventy five lesions had no surgical intervention, 149 lesions (85%) being homogenous and 20 (11%) @entity12120 , and 6 (3%) erythroplakias. Eighty-one percent of the lesions were associated with smoking. The mean size of the lesions was 503 mm(2) and 21 of the lesions (12%) exhibited @entity5115 . Sixty-five lesions were not biopsied. These @entity1 were also followed (mean 5.5 yrs, range 1.1-20.2 yrs), and biopsies taken in case of changes indicative of malignant development. All @entity1 were encouraged to quit smoking and @entity281 were treated. The possible role of different variables for malignant development was estimated by means of logistic regression analysis. Following surgical treatment 11 lesions (12%) developed @entity189 after a mean follow-up period of 7.5 yrs. Non-homogenous @entity12120 accounted for the highest frequency of malignant development, i.e. 20%, whereas 3% of the homogenous @entity12120 developed @entity189 . Surgically treated lesions with slight, moderate, severe and no @entity5115 developed @entity189 with similar frequencies, i.e. 9-11%. Without surgical intervention 16% of the 175 lesions disappeared whereas seven lesions (4%) developed @entity189 after a mean observation period of 6.6 yrs. The highest frequency of malignant development (15%) was seen for @entity12120 , this figure being 3% for homogenous @entity12120 . Fourteen percent of lesions with slight @entity5115 developed @entity5 and 2% of lesions with no @entity1141 showed @entity5 . Logistic regression analysis showed a seven times increased risk (OR = 7.0) of @entity12120 for malignant development as compared with homogenous @entity12120 and a 5.4 times increased risk for malignant development for lesions with a size exceeding 200 mm(2). No other examined variables including presence of any degree of @entity5115 , site, demarcation, smoking and surgical intervention were statistically significant factors for malignant development.

title: Long-term treatment outcome of oral XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5115 :: ('MESH:C567703', 'Disease') :: ['epithelial dysplasia']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['premalignant lesions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant transformation', 'malignancy']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucosal flaps']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'carcinoma']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['candidal infections']

entities_list: @entity12120 :: ('MESH:D007971', 'Disease') :: ['non-homogenous leukoplakias', 'non-homogenous leukoplakia', 'leukoplakias', 'leukoplakia']

entities_list: @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia']

answer: @entity75 :: (MESH:D001927,Disease) :: ['premalignant lesions']


abstract: OBJECTIVE: To assess the effectiveness and safety of the @entity3303 patch 5%, a targeted peripheral analgesic, in the treatment of @entity14000 , @entity3949 , and @entity1643 @entity1 with incomplete responses to their current analgesic treatment regimen containing @entity2682 . DESIGN: This was a 2-week, open-label, nonrandomized, multicenter pilot trial in the clinical setting. @entity1 with @entity14000 , @entity3949 , or @entity1643 with partial responses (average daily @entity158 intensity >4/10) to their current analgesic treatment regimen were included. Treatment consisted of daily application of up to four @entity3303 patches to areas of maximal @entity158 . Effectiveness was evaluated using the Brief Pain Inventory (BPI). Safety was assessed by adverse events, physical and neurologic examinations, vital signs, and clinical laboratory tests. RESULTS: Significant improvements in BPI measures of @entity158 intensity and @entity158 relief were reported for all groups of @entity1 after 2 weeks of @entity3303 patch 5% treatment. Significant improvements in BPI measures of @entity158 interference with general activity, mood, walking ability, normal work, relationships with others, sleep, and enjoyment of life were noted. The @entity3303 patch 5% was found to be safe and well tolerated. CONCLUSIONS: Results of this study highlight the potential advantages achieved with rational polypharmacy using a targeted peripheral analgesic, the @entity3303 patch 5%, with centrally acting agents such as the anticonvulsant @entity2682 . Controlled trials are warranted to further define the impact of such combination therapy.

title: XXXX patch 5% with systemic analgesics such as @entity2682 : a rational polypharmacy approach for the treatment of chronic pain.

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['low back pain']

entities_list: @entity2682 :: ('MESH:C040029', 'Chemical') :: ['gabapentin']

entities_list: @entity3949 :: ('MESH:D003929', 'Disease') :: ['painful diabetic neuropathy']

entities_list: @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'peripheral pain']

entities_list: @entity14000 :: ('MESH:D051474', 'Disease') :: ['postherpetic neuralgia']

answer: @entity3303 :: (MESH:D008012,Chemical) :: ['Lidocaine']


abstract: The aim of this study was to assess the luteinizing hormone (LH) and follicle stimulating hormone (FSH) pulsatile secretion and their temporal relation (concordance) in subjects with @entity3610 ( @entity3610 ). Fifteen subjects were included in the study (age 17-30 years, body mass index (BMI) 19.38-33.46 kg/m2). For the LH and FSH determinations, blood sampling started at 23.00 and lasted for 6 h with an intersample interval of 10 min. Pulse analysis was carried out using the PulsDetekt program. LH/FSH pulse concordance was calculated using the specific concordance index. Gonadotropin co-pulsatility was found in six subjects who were significantly younger than the others (median 18.5 vs. 22.5 years, p = 0.036). BMI, hirsutism grade, insulin sensitivity, @entity53 , @entity1420 , @entity251 , prolactin, @entity701 and results obtained from the pulsatility analysis did not significantly differ between the groups. A serum @entity701 concentration was correlated with the increased LH/FSH lag time (p = 0.851, p = 0.036) all subjects were included. In conclusion, two distinct LH/FSH secretory patterns were found in @entity3610 @entity1 , manifested by the presence or absence of the concordance of gonadotropin secretion. In the group where LH/FSH co-pulsatility was present, correlation was found between the serum @entity701 and the LH/FSH lag. We also confirmed the finding of previous studies that LH and FSH secretion are regulated by two different mechanisms.

title: Temporal coupling of luteinizing hormone and follicle stimulating hormone secretion in XXXX .

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovary syndrome', 'PCOS']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol']

answer: @entity3610 :: (MESH:D011085,Disease) :: ['polycystic ovary syndrome']


abstract: BACKGROUND: Resilience, characterized by an ability to bounce back or recover from stress, is increasingly recognized as a psychometric property affecting many outcomes' domains including quality of life, suicide risk in active-duty military personnel, and recovery in @entity5 @entity1 . This study examines the correlation between resilience, as measured by the Brief Resilience Scale ( @entity4375 ), and traditional outcome scores including the American Shoulder and Elbow Surgeons (ASES), Single Assessment Numeric Evaluation (SANE), and Penn scores in @entity1 undergoing @entity348 ( @entity348 ). METHODS: Seventy @entity1 undergoing primary anatomic @entity348 were followed up for a minimum of 2   years (mean, 30        3 months). @entity1 were stratified into groups a priori, based on deviation from the mean of the @entity4375 score, into low-resilience (LR), normal-resilience (NR), and high-resilience (HR) @entity1 , and outcome scores were calculated for each group. RESULTS: Postoperative @entity4375 scores significantly correlated with ASES, Penn, and SANE scores (r   =   0.41-0.44, P   <   .004 for all scores). When we evaluated @entity1 based on resilience group, the LR group had a Penn score that was 34 points lower than that in the HR group. Likewise, the LR group had a SANE score that averaged 40 points lower than that in the HR group (SANE score of 53 points in LR group and 92 points in HR group, P   =   .05). When we evaluated ASES subscores, it appeared that the @entity158 subscale was responsible for most of the difference between the LR and HR groups (29 points and 48 points [out of 50 points], respectively; P   =   .03). CONCLUSIONS: Resilience is a major predictor of postoperative outcomes after @entity348 . @entity1 who are classified as having LR have outcome scores that are 30 to 40 points lower on traditional outcome scales than @entity1 with HR.

title: Resilience correlates with outcomes after XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity348 :: ('MESH:C535338', 'Disease') :: ['total shoulder arthroplasty', 'TSA']

answer: @entity348 :: (MESH:C535338,Disease) :: ['total shoulder arthroplasty']


abstract: PURPOSE/OBJECTIVES: To explore ethnic differences in @entity458 and social withdrawal after receiving an abnormal mammogram result and to assess if coping strategies mediate ethnic differences. DESIGN: Descriptive correlational. SETTING: Two urban mobile mammography units and a rural community hospital in the state of Washington. SAMPLE: 41 Latina and 41 non-Latina Caucasian (NLC) @entity1 who had received an abnormal mammogram result. METHODS: @entity1 completed standard sociodemographic questions, Impact of Event Scale-Revised, the social dimension of the Psychological Consequences Questionnaire, and the Brief @entity5786 . MAIN RESEARCH VARIABLES: Ethnicity, @entity458 , social withdrawal, and coping. FINDINGS: Latinas experienced greater @entity458 and social withdrawal compared to NLC counterparts. Denial as a coping strategy mediated ethnic differences in @entity458 . Religious coping mediated ethnic differences in social withdrawal. CONCLUSIONS: Larger population-based studies are necessary to understand how ethnic differences in coping strategies can influence psychological outcomes. This is an important finding that warrants additional study among @entity1 who are and are not diagnosed with @entity0 following an abnormal mammogram. IMPLICATIONS FOR NURSING: Nurses may be able to work with Latina @entity1 to diminish denial coping and consequent distress. Nurses may be particularly effective, given cultural values concerning strong interpersonal relationships and respect for authority figures.

title: XXXX , social withdrawal, and coping following receipt of an abnormal mammogram among different ethnicities: a mediation model.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['psychological distress']

answer: @entity458 :: (MESH:D020018,Disease) :: ['Psychological distress']


abstract: Preschoolers who belonged to the high (Group I, n = 112) or the low (Group II, n = 90) socio-economic stratum were followed prospectively for six months. Mean monthly incidence of @entity294 was 3 and 7 episodes per 100 @entity1 for Group I and Group II respectively (p less than 0.001). Episodes were shorter and affected a smaller proportion of @entity1 in Group I (p less than 0.002 and p less than 0.05), respectively). Bacterial enteropathogens were recovered in 12.6% and 13.5% of the episodes in Group I and Group II and parasites in 15.4% and 62.8%, respectively. Rotavirus was detected once in each group. Asymptomatic carrier rates for enteropathogenic bacteria were 12.0% in Group I and 7.2% in Group II. The corresponding figures for parasites were 28.2% and 62.8% (p less than 0.001). Nutritional status was normal in all @entity1 . These results suggest that socio-economic stratum plays an important role in the characteristics of @entity221 in the groups which conform the population of the less developed countries. Acute @entity294 is less frequent in preschoolers living in Santiago than in other developing areas. Rates of @entity4092 are high.

title: Acute @entity294 and XXXX in Chilean preschoolers of low and high socio-economic strata.

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['diarrhoeal illness']

entities_list: @entity4092 :: ('MESH:D058345', 'Disease') :: ['asymptomatic infection']

answer: @entity4092 :: (MESH:D058345,Disease) :: ['asymptomatic infection']


abstract: BACKGROUND: @entity170 is a health care issue in which family physicians play a major role. Although awareness of @entity170 is high, recent studies suggest that application of recent advances in its treatment to the clinical setting may be low. We have developed a problem-based learning intervention for @entity170 in which paired rheumatologists and family physicians developed nine problem-solving clinical scenarios. An educational matrix was used to link specific case scenarios with individual teaching objectives, developed via a previous needs assessment. Family physicians participated in the workshop, developing best practice responses to the clinical scenarios with a trained facilitator and content expert. METHODS: To assess the impact of this intervention, family physicians participated in a pre- and post-test evaluation, using objective structured clinical examinations and standardized @entity1 . Objective structured clinical examination stations tested knowledge, skills, and judgment relating to @entity170 with respect to risk factors, use of appropriate investigations including bone mineral densitometry (BMD), strategies for the prevention of @entity170 (both pharmacologic and nonpharmacologic), treatment options for established @entity170 (bisphosphonates and hormone replacement therapy), and management of @entity174 . @entity1 were evaluated using a predetermined score generated by their responses to objective structured clinical examinations and standardized @entity1 (max. score = 101). Evaluations were conducted anonymously, although @entity1 had access to their own pre- and post-test results for personal feedback. The impact of the workshop was assessed by comparing pre- and post-test responses by group, by individual, and by station. RESULTS: @entity1 demonstrated a significant improvement in their post-workshop scores. Of 40 @entity1 , 26 showed improvement in score (> +10), 13 showed modest change (+1 to +10), and 1 showed a marked decrease (> -10). The greatest improvements were seen in the management of the male @entity170 @entity1 , determination of risk factors for @entity170 , and the use and interpretation of bone mineral densitometry. Family physicians reported general satisfaction with the content and format of both the workshop and the evaluation process. IMPLICATIONS: We conclude that this type of problem-based learning intervention workshop results in improved knowledge, skills, and judgment in the management of @entity170 by family physicians as objectively assessed using a pre- and post-test format including objective structured clinical examinations and standardized @entity1 .

title: Evaluation of a problem-based learning workshop using pre- and post-test objective structured clinical examinations and standardized XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient', 'Participants']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['Osteoporosis', 'osteoporosis']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['recent osteoporosis fracture']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVES: Magnetic resonance angiography with three-dimensional surface rendering was performed to determine its value in assessing anatomic detail in @entity1 with suspected @entity449 . BACKGROUND: Dacron patch aortoplasty repair of @entity1498 carries an inherent risk of @entity439 development. @entity944 from @entity1755 prompted discontinuing this operation and evaluating 39 @entity1 (16 @entity1 ; mean age 6.3 years, range 10 days to 14.5 years) undergoing repair between January 1976 and October 1987. The aorta ruptured in 10 @entity1 ; 6 died at a mean interval of 8.1 years (range 0.75 to 12.4) after repair. All 33 survivors were interviewed and examined. METHODS: Conventional magnetic resonance imaging was performed in 26 @entity1 , magnetic resonance angiography in 18. Angiographic slices were used to reconstruct three-dimensional images. No catheterization or contrast angiography was performed. Surgical intervention was based on clinical findings and magnetic resonance images. RESULTS: Twenty @entity1 (11 @entity1 ) developed @entity439 , of which nine were detected in @entity1 studied by magnetic resonance. @entity397 occurred in eight female @entity1 , three of whom were pregnant. Surface renderings accurately defined aortic anatomy or @entity439 in all @entity1 . On follow-up, no @entity439 have been detected in @entity1 with negative magnetic resonance study results. Precise anatomic correlation with operative findings was reported. CONCLUSIONS: Magnetic resonance angiography with three-dimensional surface rendering provides noninvasive, radiation-free and contrast agent-free high resolution images of the thoracic aorta. These images can be reviewed and have three-dimensional form and perspective. These techniques were preferred over invasive angiography by surgeons and clinicians as definitive, risk-free procedures before surgical intervention.

title: Incidence of XXXX formation after Dacron patch aortoplasty repair for @entity1498 : long-term results and assessment utilizing magnetic resonance angiography with three-dimensional surface rendering.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'girls']

entities_list: @entity449 :: ('MESH:D001014', 'Disease') :: ['aortic aneurysms']

entities_list: @entity1755 :: ('MESH:D001019', 'Disease') :: ['aortic rupture']

entities_list: @entity944 :: ('MESH:D003645', 'Disease') :: ['Sudden death']

entities_list: @entity1498 :: ('MESH:D001017', 'Disease') :: ['coarctation of the aorta']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'aneurysm']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['Ruptures']

answer: @entity439 :: (MESH:D000783,Disease) :: ['aneurysm']


abstract: We have analysed in vitro the complement-fixing activity of anticardiolipin antibodies (C-fix aCL) from @entity1 with persistent and moderate/high titres IgG aCL antibodies: 21 with @entity715 and 11 without @entity715 . Titre and C-fix ability of aCL were measured by ELISA. @entity12009 and non- @entity12009 @entity1 were similar with regard to mean levels of IgG aCL (46 +/- 24 versus 51 +/- 30 GPL, P = 0.7), frequency of IgM aCL (P = 0.7) and a comparable predominance of IgG2 aCL reactivity on ELISA (95% versus 100%, respectively, P = 1.0). Remarkably, a high frequency of C-fix aCL (71% versus 92%, P = 0.35) was observed in both groups. Similarly, no difference was observed in the mean level of C-fix aCL in @entity12009 and non- @entity12009 @entity1 (7 +/- 6 versus 9 +/- 8 SDunits, P = 0.3). Analysis of 10 primary and 11 secondary @entity12009 also revealed a comparable IgG aCL mean titre (57 +/- 29 versus 37 +/- 11, P = 0.06), frequency of IgM aCL (P = 0.6) and of C-fix aCL (70% versus 73%, P = 0.99). Among @entity12009 @entity1 six had exclusive arterial events and seven exclusive @entity455 . The IgG aCL mean titre (36 +/- 10 versus 36 +/- 11 GPL, P = 0.9) and the frequency of IgM aCL antibodies (P = 0.56) in these subgroups of @entity1 were comparable. There was a trend of higher frequency of C-fix aCL in @entity1 with exclusive @entity455 (100%) compared to 50% of those with exclusive arterial events (p = 0.07). Importantly, C-fix aCL titre was higher in the former group compared to the later one (8 +/- 5 SDunits versus 2 +/- 2 SDunits, P = 0.016). Our data support the notion of a high frequency of C-fix aCL in @entity12009 . Although it does not discriminate those @entity1 without @entity715 events with persistent moderate/high levels of aCL, this property seems to be more relevant in @entity455 and may provide the basis for further understanding the distinct pathogenic mechanisms underlying arterial and @entity432 of @entity12009 .

title: Complement-fixing activity of anticardiolipin antibodies in @entity1 with and without XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['venous events']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['venous occlusive disorders']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis', 'thrombotic']

answer: @entity715 :: (MESH:D013927,Disease) :: ['thrombosis']


abstract: BACKGROUND: Isolation and characterization of circulating @entity5 cells (CTCs) in @entity1 suffering from a variety of different @entity5 have become hot biomarker topics. In this study, we evaluated the prognostic value of CTCs in @entity788 . MATERIALS AND METHODS: Initial literature was identified using Medline and EMBASE. The primary data were hazard ratios (HRs) with 95% confidence intervals (CIs) of survival outcomes, including @entity1349 ( @entity1349 ) and progression free survival/recurrence free survival (PFS/ @entity4434 ). RESULTS: A total of 9 eligible studies were included in this meta-analysis, published between 2002 and 2013. The estimated pooled HR and 95%CI for @entity1349 for all studies was 1.64 (95%CI 1.39-1.94, p<0.00001) and the pooled HR and 95%CI for @entity4434 /DFS was 2.36 (95%CI 1.41-3.96, p<0.00001). The HRs and 95%CIs for @entity1349 and @entity4434 / DFS in @entity1 before treatment were 1.93 (95%CI 1.26-2.96, p=0.003) and 1.82 (95%CI 1.22-2.72, p=0.003), respectively. In @entity1 receiving treatment, the HRs and 95%CI for @entity1349 and @entity4434 /DFS were 1.37 (95%CI 1.00- 1.86, p=0.05) and 1.89 (95%CI 1.01-3.51, p=0.05), respectively. Moreover, the pooled HR and 95%CI for @entity1349 in the post-treatment group was 2.20 (95%CI 0.80-6.02, p=0.13) and the pooled HR for @entity4434 /DFS was 8.36 (95%CI 3.22-21.67, p<0.0001). CONCLUSIONS: The meta-analysis provided strong evidence supporting the proposition that CTCs detected in peripheral blood have a fine predictive role in pancreatic @entity1 especially on the time point of post-treatment.

title: Prognostic role of circulating XXXX cells in @entity1 with @entity788 : a meta-analysis.

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: PURPOSE: The purpose of this study was to evaluate the efficacy of portal venous (PV) stent placement and find groups who benefit from this procedure among @entity1 with symptomatic PV @entity101 caused by @entity5 . MATERIALS AND METHODS: From October 2001 to January 2013, 13 @entity1 underwent PV stent placement because of @entity1211 or @entity432 caused by @entity1126 (n  =  7), @entity788 (n  =  5), or nodal @entity3 (n  =  1). Technical success, changes in PV pressure gradient and palliative prognostic index (PPI) scores before and after stent placement, clinical outcomes, and complications were evaluated. RESULT: Stent was successfully placed in all @entity1 (100  %, 13/13), lowering the mean PV pressure gradient from 12.4      4.5  mmHg (range 5-20  mmHg) to 0.5      0.9  mmHg (range 0-3  mmHg, p  <  0.000001). Symptoms were improved in all but one @entity1 (92.3  %, 12/13). Although 10 @entity1 (76.9  %, 10/13) with pre-stent placement PPI scores lower than 6 (mean 3.5      1.7, range 0-5) were discharged from the hospital, the other 3 with the pre-stent placement PPI of 6 or more (mean 7.2      1.6, range 6-9.5) died within 4  weeks (range 17-28  days) without discharge. The median survival time of discharged @entity1 was 123  days, and it was 20  days in non-discharged @entity1 (p  =  0.0001). A major procedure-related complication of intraperitoneal @entity548 occurred in one @entity1 (7.7  %, 1/13). No significant factor was detected for the occurrence of complication. CONCLUSION: PV stent placement is a feasible, safe, and effective technique to relieve symptomatic PV @entity101 caused by @entity5 . The PPI score might be useful to stratify @entity1 who benefit from this procedure.

title: Portal Venous Stent Placement for Malignant Portal XXXX or Occlusion: Who Benefits?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant tumors']

entities_list: @entity1126 :: ('MESH:D001650', 'Disease') :: ['bile duct cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['occlusion']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['PV stenosis']

answer: @entity1211 :: (MESH:D054556,Disease) :: ['Venous Stenosis']


abstract: BACKGROUND: The literature regarding the different patterns of atlas and @entity130 and their appropriate management and the progressive development in the management of these injuries is scarce from our world, so we presenting here our experience of management of these injuries by applying Halovest. MATERIALS AND METHODS: Thirty @entity1 (22 males, 8 females) with atlas and @entity130 were treated and then followed-up for an average of 24 months. The data was analysed with respect to @entity130 and use of Halovest in the treatment of these injuries. The @entity1 with neuro defecit were scored as per ASIA grading scale (from Grade A to Grade E). RESULTS: The halo-vest immobilization was used for a mean period of 12    3weeks (range 9 to 15 weeks) for atlas and @entity130 . Four @entity1 had neurodeficit. Two @entity1 recovered from ASIA Grade C to ASIA Grade D. One @entity1 improved from ASIA grade D to ASIA grade E while as one @entity1 with neurodeficit was lost to follow up. No @entity204 or worsening of the neurodeficit was observed during the follow up period. CONCLUSION: The clinical as well as radiological outcome of these injuries is mostly satisfactory with the conservative management using Halovest. More studies should be conducted to form the guidelines regarding @entity1 selection for conservative management using halovest.

title: Atlas and XXXX role of Halovest.

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['type of injury', 'axis injuries']

answer: @entity130 :: (MESH:D014947,Disease) :: ['axis injuries']


abstract: OBJECTIVE: Recent studies have indicated that coronary artery bypass grafting (CABG) outcomes in @entity1 with prior stents are suboptimal. We aimed to study the impact of prior percutaneous coronary intervention (PCI) with stenting (PCI-S) on late CABG mortality in @entity6 @entity1 with @entity66 . METHODS: We reviewed the primary nonemergency CABG experience from a single U.S. institution (n  =  7005; 1996-2007, Toledo, Ohio). Diabetics with @entity66 (n  =  1583) were identified and divided into 2 groups: (1) prior PCI-S (n  =  202); and (2) no prior PCI (No-PCI [n  =  1381]). Hierarchic Cox proportional hazards models were used to assess the effect of prior PCI-S on 5-year mortality after CABG. A propensity score for PCI-S and No-PCI @entity1 was derived using a nonparsimonious logistic regression and used to generate a 1:1 (PCI-S to No-PCI) matched cohort. RESULTS: In model 1, after adjusting for preoperative clinical characteristics, medications, off-pump surgery, and isolated CABG surgery status, prior PCI-S was associated with a 39% increased risk of mortality (hazard ratio [HR]  =  1.39, with 95% confidence interval [CI; 1.02, 1.90]; P  =  .04). Further adjustment for date of surgery (model 2) (HR  =  1.39, with 95% CI [1.02, 1.91]; P  =  .04) or operative parameters (model 3) (HR  =  1.38, with 95% CI [1.01, 1.88]; P  =  .046) did not alter the association. The 1:1 matched-cohort analysis confirmed the increased risk associated with PCI-S (HR  =  1.61, with 95% CI [1.03, 2.51]; P  =  .037). CONCLUSIONS: @entity1 who have both @entity6 , and have undergone prior PCI-S, have  poorer long-term outcomes after CABG compared with those who have had no prior PCI-S.

title: Impact of prior intracoronary stenting on late outcomes of coronary artery bypass surgery in diabetics with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['triple-vessel disease']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes and triple-vessel disease']

answer: @entity66 :: (MESH:D004194,Disease) :: ['triple-vessel disease']


abstract: BACKGROUND: Bent tail is a @entity19 model for @entity62279 ( @entity601 ) that is characterized by the presence of @entity601 , a delayed posterior neuropore closure, and a tail phenotype. In addition, Bent tail shows laterality defects and increased prenatal mortality. The @entity600 of this @entity19 are caused by a submicroscopic deletion that completely encompasses the gene coding for the @entity219 finger transcription factor @entity62645 . In this study we investigated the sensitivity of the phenotype of Bent tail to the nutrients @entity4181 , @entity8580 , and @entity219 . These nutrients are thought to be involved in the etiology of @entity601 , in combination with a genetic predisposition. METHODS: The most penetrant phenotype of the Bent tail @entity19 , the tail @entity600 , was used as a marker for the nutrient sensitivity of the neural phenotype. The size of the litters and the survival of the offspring, subdivided according to genotype, were analyzed as markers for the nutrient sensitivity of other phenotypic features of Bent tail. RESULTS: In confirmation of earlier studies, we observed the prenatal loss of a number of homozygous females and hemizygous males, as well as the effect of genotype on the tail phenotype of Bent tail. However, periconceptional supplementation of the maternal diet with @entity4181 , @entity8580 , or @entity219 produced no significant effects on either the tail phenotype of the offspring or the size and genotypic composition of the litters. CONCLUSIONS: Bent tail appears to be a @entity4181 -, @entity8580 -, and @entity219 -insensitive @entity19 model for @entity601 .

title: Phenotype of the neural tube defect XXXX model bent tail is not sensitive to maternal @entity4181 , @entity8580 , or @entity219 supplementation.

entities_list: @entity4181 :: ('MESH:D002955', 'Chemical') :: ['folinic acid']

entities_list: @entity8580 :: ('MESH:D007294', 'Chemical') :: ['myo-inositol']

entities_list: @entity62279 :: ('MESH:C536410', 'Disease') :: ['X-linked neural tube defects']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['congenital malformations', 'malformation']

entities_list: @entity601 :: ('MESH:D009436', 'Disease') :: ['exencephaly', 'NTDs']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: PURPOSE: @entity39 is an important determinant of @entity1 outcome in @entity656 ( @entity656 ). This prospective study was conducted to evaluate if perfusion CT (PCT) can predict the development of @entity39 at an early stage in @entity656 . METHODS: PCT was performed within 72  h of @entity490 in 57 consecutive admitted @entity1 of @entity656 , out of which four @entity1 were excluded. Thirty-two @entity1 were classified as @entity656 and 21 as @entity656 ( @entity656 ) on the basis of APACHE II or SIRS criteria or presence of organ failure. All @entity1 underwent a follow-up CECT at 3  weeks to look for @entity39 . RESULTS: Out of 32 @entity1 of @entity656 , 14 @entity1 showed perfusion defects. The mean blood flow (BF) in these areas was 11.47      5.56  mL/100  mL/min and median blood volume (BV) was 3.92  mL/100  mL (0.5-8.49  mL/100  mL). All these @entity1 developed @entity39 on follow-up scan. Two @entity1 who did not show perfusion defects also developed @entity39 . Remaining 37 @entity1 (16 @entity656 and 21 @entity656 ) did not show perfusion defect and did not develop @entity39 on follow-up. All regions showing BF less than  <=23.45  mL/100  mL/min and BV  <=8.49  mL/100  mL developed @entity39 . The values of perfusion parameters may vary with the scanner, mathematical model and protocol used. The sensitivity and specificity of PCT for predicting @entity39 were 87.5% and 100%, respectively. The cut off values of BF and BV for predicting the development of @entity39 were 27.29  mL/100  mL/min and 8.96  mL/100  mL, respectively, based on ROC curve. PCT is a reliable tool for early prediction of @entity39 , which may open new avenues to prevent this ominous complication.

title: Perfusion CT: Can it predict the development of XXXX in early stage of @entity656 ?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity656 :: ('MESH:D019283', 'Disease') :: ['SAP', 'MAP', 'severe acute pancreatitis', 'mild acute pancreatitis', 'acute pancreatitis']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis', 'pancreatic necrosis', 'Pancreatic necrosis']

answer: @entity39 :: (MESH:D009336,Disease) :: ['pancreatic necrosis']


abstract: Sympathetic overactivity and low parasympathetic activity is an @entity5433 ( @entity5433 ) which enhances cardiac mortality. In the present study, the impact of @entity5433 on the mortality in @entity1 after @entity583 was evaluated. We examined 162 @entity1 7-21 days after @entity583 , 20 @entity1 of whom died in the course of two years. Baroreflex sensitivity ( @entity4375 ) was estimated by spectral analysis of spontaneous @entity551 and cardiac intervals (Finapres, 5 min recording, controlled breathing 20/min). The heart rate variability was determined as SDNN index (mean of standard deviations of RR intervals for all 5-min segments of 24-hour ECG recordings). @entity4375 < 3 ms/mm Hg and/or SDNN index < 30 ms were taken as markers of @entity5433 . The risk stratification was performed according to the number of the following standard risk factors of increased risk of cardiac mortality ( @entity2855 ): ejection fraction < 40%, positive late potentials and the presence of ventricular extrasystoles > 10/h. No difference in mortality between @entity1 with @entity5433 (4%) and without @entity5433 (4.5%) was found in 92 @entity1 without @entity2855 , the mortality in 6 @entity1 with three @entity2855 was 66.6%. Five of these @entity1 had @entity5433 . Out of 64 @entity1 with one or two @entity2855 , 32 had @entity5433 . The mortality of @entity1 without @entity5433 was 6.25% and 31.2% of those with @entity5433 (p<0.025). It is concluded that @entity5433 enhanced two-years mortality five fold in our @entity1 with moderate risks.

title: Baroreflex sensitivity determined by spectral method and heart rate variability, and two-years mortality in @entity1 after XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity5433 :: ('MESH:C563939', 'Disease') :: ['AD', 'autonomic dysfunction']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['fluctuations of systolic blood pressure']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarction']


abstract: @entity950 ( @entity950 ) is a rare @entity74 characterized by @entity344 . We present a new pathogenic mutation of the @entity1594 gene and illustrate the need for a multidisciplinary health care approach to facilitate the correct diagnosis. The @entity1 , a 47-year-old Caucasian @entity1 , was diagnosed with @entity417 at the age of 12. During the following 30 years, she developed numerous gastrointestinal @entity1127 . The @entity1 underwent several operations, and suffered chronic @entity490 , @entity3147 , and @entity281 . Screening of the @entity1594 gene revealed a novel, disease-causing mutation. In 2012, the @entity1 suffered @entity4988 and a large polyp in the small bowel was found. Gamma globulin was given but the @entity1 responded with @entity221 and @entity683 -like symptoms and refused more treatment. The @entity1 underwent surgery in 2014 and made an uneventful recovery. At follow-up two months later albumin was 38   g/L and IgG was 6.9   g/L. Accurate diagnosis is essential for medical care. For @entity1 with complex symptomatology, often with @entity395 , this is best provided by multidisciplinary teams including representatives from clinical genetics. @entity1 with a @entity1594 mutation should be followed up both for @entity950 and @entity1884 and may develop @entity6518 and @entity465 .

title: A Novel @entity1594 Mutation Causing Severe @entity950 with XXXX , @entity465 , and @entity1884 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'Patients', 'woman', 'patients']

entities_list: @entity395 :: ('MESH:D035583', 'Disease') :: ['rare diseases']

entities_list: @entity4988 :: ('MESH:D034141', 'Disease') :: ['hypoalbuminemia']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['juvenile polyps of the gastrointestinal tract']

entities_list: @entity1884 :: ('MESH:D013683', 'Disease') :: ['haemorrhagic hereditary telangiectasia']

entities_list: @entity6518 :: ('MESH:D011504', 'Disease') :: ['protein loosing enteropathy']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['multiple infections']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza']

entities_list: @entity465 :: ('MESH:D007153', 'Disease') :: ['immunodeficiency']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic disorder']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']

entities_list: @entity950 :: ('MESH:C537702', 'Disease') :: ['JPS', 'Juvenile polyposis syndrome']

answer: @entity6518 :: (MESH:D011504,Disease) :: ['Protein Losing Enteropathy']


abstract: Treatment of pathologic @entity2249 secondary to extensive lesions of @entity82 and simple @entity2001 has been controversial. We think that modified Pauwels' intertrochanteric osteotomy and osteosynthesis can result in sound healing of the lesion and of the @entity174 , with no recurrence, low complication rates, and good functional results. Seven @entity1 were treated with a uniform approach consisting of biopsy (Stage I) and osteotomy with osteosynthesis (Stage II). Curettage of the lesion and bone grafting were not done. The average followup was 79.28 months (range, 32-142 months). All of the @entity174 and osteotomy sites healed in means of 14 weeks (range, 12-16 weeks) and 9.1 weeks (range, 8-10 weeks), respectively. All @entity82 lesions healed radiologically. Grade IV radiographic healing was seen in both @entity1 with simple @entity2001 after 35 and 92 months. Using the Musculoskeletal Tumor Society functional evaluation and Toronto Extremity Salvage Score, all the @entity1 had good to excellent results. Complications such as @entity281 , local recurrence, refracture, femoral @entity85 , @entity2530 of the femoral head, and growth arrest of capital femoral physis were not seen. In addition to biomechanical advantages, the procedure seems to have had a biologic role in healing of the @entity174 and of the lesion by initiating osteogenesis to replace the defect with new bone. LEVEL OF EVIDENCE: Therapeutic study, Level IV (case series--no, or historical control group). See the Guidelines for Authors for a complete description of levels of evidence.

title: Treatment of pathologic XXXX with modified Pauwels' osteotomy.

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrous dysplasia']

entities_list: @entity2249 :: ('MESH:D005265', 'Disease') :: ['femoral neck fractures']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture']

entities_list: @entity2001 :: ('MESH:D001845', 'Disease') :: ['bone cysts']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['neck deformity']

entities_list: @entity2530 :: ('MESH:D010020', 'Disease') :: ['osteonecrosis']

answer: @entity2249 :: (MESH:D005265,Disease) :: ['femoral neck fractures']


abstract: Peritoneal @entity2269 with divergent differentiation are recently described highly aggressive @entity5 with characteristic clinical, morphologic, and immunohistochemical features. This review covers 38 cases that have been reported in the literature. The average age of @entity1 is 18.4 years, and males are affected twice as frequently as females. @entity5 generally present as multiple peritoneal nodules without obvious organ involvement. Histology shows islands of small cells set in dense @entity2269 . Immunohistochemical stains are usually positive for cytokeratins, epithelial membrane antigen, @entity2283 , and @entity2277 . Many cases also stain for @entity3508 but rarely for other neuroepithelial markers. Ultrastructural appearances range from undifferentiated small cells to larger epithelial elements. Paranuclear aggregates of intermediate filaments are characteristic. Dense-core granules and other neuroendocrine features have been described in a minority of cases. Some @entity5 respond to chemotherapy, but most @entity1 die within months to a few years. The histogenesis of these @entity5 is uncertain.

title: Peritoneal XXXX with divergent differentiation: a review.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumors', 'neoplasms', 'tumors']

entities_list: @entity2269 :: ('MESH:D058405', 'Disease') :: ['desmoplastic small round cell tumors', 'desmoplastic stroma']

entities_list: @entity3508 :: ('2026', 'Gene') :: ['neuron-specific enolase']

answer: @entity2269 :: (MESH:D058405,Disease) :: ['desmoplastic small round cell tumors']


abstract: BACKGROUND AND OBJECTIVE: In some situations, the use of muscle relaxants (neuromuscular blocking drugs) are undesirable or contraindicated. We compared intubating conditions without muscle relaxants in premedicated @entity1 receiving either @entity680 40 microg kg(-1) or @entity1937 2, 3 or 4 microg kg(-1) followed by @entity1875 2 mg kg(-1). METHODS: In a randomized, double-blind study, 80 healthy @entity1 were assigned to one of four groups (n = 20). After intravenous @entity3897 , @entity680 40 microg kg(-1) or @entity1937 2, 3 or 4 microg kg(-1) were injected over 90 s followed by @entity1875 2 mg kg(-1). Ninety seconds after administration of the @entity1875 , laryngoscopy and tracheal intubation were attempted. Intubating conditions were assessed as excellent, good or poor on the basis of ease of lung ventilation, jaw relaxation, laryngoscopy, position of the vocal cords, and @entity1 response to intubation and slow inflation of the endotracheal tube cuff. RESULTS: Seven @entity1 who received @entity1937 2 microg kg(-1) and one @entity1 who received @entity1937 3 microg kg(-1) could not be intubated at the first attempts. Excellent intubating conditions (jaw relaxed, vocal cords open and no movement in response to tracheal intubation and cuff inflation) were observed in those who received either @entity680 40 microg kg(-1) (45% of @entity1 ) or @entity1937 in doses of 2 microg kg(-1) (20%), 3 microg kg(-1) (75%) or 4 microg kg(-1) (95%). Overall, intubating conditions were significantly better (P < 0.05), and the number of @entity1 showing excellent conditions were significantly higher (P < 0.05) in @entity1 who received @entity1937 4 microg kg(-1) compared with those who received @entity680 40 microg kg(-1) or @entity1937 2 microg kg(-1). No @entity1 needed treatment for @entity551 or @entity1168 . CONCLUSIONS: @entity1937 4 microg kg(-1) and @entity1875 2 mg kg(-1) administered in sequence intravenously provided good or excellent conditions for tracheal intubation in all @entity1 without the use of muscle relaxants.

title: Tracheal intubation without muscle relaxants: @entity1937 or XXXX in combination with @entity1875 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity680 :: ('MESH:D015760', 'Chemical') :: ['alfentanil']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol']

entities_list: @entity3897 :: ('MESH:D001285', 'Chemical') :: ['atropine']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

entities_list: @entity1937 :: ('MESH:C071741', 'Chemical') :: ['remifentanil', 'Remifentanil']

answer: @entity680 :: (MESH:D015760,Chemical) :: ['alfentanil']


abstract: STUDY OBJECTIVES: The purpose of this study was to assess the clinical follow-up of a negative @entity4649 ( @entity4649 ) angiographic finding after a suspicion of @entity1151 ( @entity1151 ) in a population of inpatients with @entity299 . In this high-risk population, clinical findings suggestive of @entity1151 are frequently misleading. DESIGN: One hundred seventy-five consecutive @entity1 hospitalized in cardiac and pneumology wards underwent @entity4649 angiography for suspected @entity1151 over a 30-month period. Angiographic findings were positive in one third. For the 117 @entity1 with negative @entity4649 angiographic findings, a clinical follow-up during a minimum of 6 months was assessed, particularly in relation to recurrent @entity1031 , mortality, and cause of @entity204 . RESULTS: The mean +/- SD follow-up was 21 +/- 11.5 months, and five @entity1 were unavailable for follow-up. Of the 117 @entity1 with negative findings, 81 @entity1 did not receive anticoagulant therapy and 46 patients received anticoagulation for @entity299 or @entity1150 . Twenty-two @entity1 died during the follow-up period, 3 of them during the first 3 months following the initial event from an undetermined cause. In @entity1 still alive, a new @entity1151 occurred in two cases. @entity1 with a poor cardiopulmonary reserve did not present any recurrent events. In this population, tests other than imaging (d-dimers, cardiac echocardiography, or venous ultrasound) contributed little to eliminate the diagnosis of @entity1151 . CONCLUSIONS: Whether or not early @entity204 are considered or not to be related to a recurrent @entity1151 , the rate of recurrence after a negative @entity4649 angiographic finding varied between 1.8% and 4.9%. @entity4649 angiography can be used confidently to rule out significant @entity1151 , and may prevent further investigations and unnecessary treatment in an inpatient population with cardiac and/or @entity1576 .

title: Clinical outcome after a negative XXXX pulmonary angiographic finding in an inpatient population from cardiology and pneumology wards.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['PE', 'acute pulmonary embolism']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep venous thrombosis']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory diseases']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac disease', 'cardiac and/or respiratory disease']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths', 'death']

answer: @entity4649 :: (MESH:C563535,Disease) :: ['spiral CT']


abstract: BACKGROUND: Endocrine measures of @entity5344 treatment may predict postchemotherapy ovarian function, providing prognostic information at the time of @entity5 diagnosis. The objectives of this study were 1) to determine whether prechemotherapy levels of antimullerian hormone ( @entity248 ), follicle-stimulating hormone (FSH), and inhibin B (inhB) are associated with the @entity2670 after chemotherapy and 2) to generate a prognostic score for ovarian recovery in young @entity1 with @entity0 . METHODS: A prospective cohort study recruited 109 @entity1 (median age, 39 years; age range, 23-45 years) before chemotherapy from 2 breast clinics and followed them longitudinally. By using time-to-event analysis, the authors tested the association between prechemotherapy @entity248 , FSH, and inhB levels and the time to @entity2670 , as measured by menstrual pattern. RESULTS: After a median follow-up of 163 days (range, 4-1009 days) after chemotherapy, 62 @entity1 (57%) experienced @entity2670 . In adjusted analyses, @entity248 levels >0.7 ng/mL (hazard ratio, 2.9; 95% confidence interval, 1.5-5.6) and FSH levels  <=10 IU/L (hazard ratio, 4.7; 95% confidence interval, 1.3-16.8) were associated with a shorter time to ovarian recovery, whereas inhB levels were not related. A prognostic score based on age <40 years, @entity248 >0.7 ng/mL, and body mass index >= 25 kg/m(2) was used to estimate the timing of recovery. CONCLUSIONS: In reproductive-aged @entity1 with newly diagnosed @entity0 , prechemotherapy @entity248 and FSH levels were associated with the @entity2670 , independent of age. A novel prognostic score incorporating @entity248 , age, and body size was capable of estimating the time to ovarian recovery. Pending validation, these data support using prechemotherapy ovarian reserve measures, particularly @entity248 , to prospectively counsel young @entity1 on future ovarian function. Because ovarian function is not equivalent to fertility, follow-up studies on predicting fertility are needed.

title: Prechemotherapy antimullerian hormone, age, and body size predict timing of @entity2670 in young @entity0 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients']

entities_list: @entity5344 :: ('MESH:D061325', 'Disease') :: ['ovarian reserve before breast cancer']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity2670 :: ('MESH:D010049', 'Disease') :: ['return of ovarian function']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Transfer of @entity5899 / @entity2891 (SBT/ @entity5579 ) into the @entity4530 fluid was studied in 10 burn @entity1 after one shot intravenous injection of 50 mg/kg SBT/ @entity5579 ( @entity5579 25 mg/kg, SBT 25 mg/kg). @entity5579 and SBT concentrations in serum and @entity4530 fluid were determined using bioassay and high performance liquid chromatography (HPLC). The concentration of @entity5579 in serum reached 109.5 +/- 9.2 micrograms/ml (mean +/- S.E.) at 0.25 hour after injection, and decreased to 6.8 +/- 2.3 micrograms/ml after 8 hours. The concentration of @entity5579 in @entity4530 fluid peaked at 4 hours and reached 28.2 +/- 8.0 micrograms/ml. The concentration of SBT in serum reached 75.7 +/- 8.3 micrograms/ml at 0.25 hour after injection, and decreased to 2.3 +/- 0.7 micrograms/ml after 8 hours. The peak concentration of SBT in @entity4530 fluid was 13.5 +/- 1.8 micrograms/ml at 3 hours. The data obtained were analysed pharmacokinetically. Cmax of @entity5579 and SBT levels in @entity4530 fluid were calculated to be 30.4 micrograms/ml and 13.6 micrograms/ml, respectively. The AUC0-8 hrs. (area under the @entity4530 fluid concentration of drug-time curve between 0 and 8 hours after injection), absorption rate constant (ka) and therapeutic AUC (AUC where drug concentrations were above minimum effective concentration) of @entity5579 were calculated to be 194.0 micrograms.hr/ml, 1.52 hr-1 and 97.1 micrograms.hr/ml (0.3-11.1 hours), respectively. The AUC0-8 hrs. and ka of SBT were also calculated as 68.3 micrograms.hr/ml and 0.62 hr-1, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Transfer of injected XXXX / @entity2891 into @entity4530 fluid].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4530 :: ('MESH:D001768', 'Disease') :: ['burn blister']

entities_list: @entity2891 :: ('MESH:D002438', 'Chemical') :: ['cefoperazone']

entities_list: @entity5899 :: ('MESH:D013407', 'Chemical') :: ['sulbactam']

answer: @entity5899 :: (MESH:D013407,Chemical) :: ['sulbactam']


abstract: @entity281 that involve the right side of the heart present their own unique etiologies, pathophysiologies, clinical manifestations, and therapeutic issues. The pathology of the @entity47 of right-sided @entity884 is identical to that of left-sided @entity884 . These @entity47 are irregular, friable masses of varying size the contain platelets, fibrin, RBCs, and microorganisms. These lesions serve as a nidus for @entity281 and produce sustained @entity2259 . Right-sided @entity884 occurs in 5% to 10% of all cases of @entity884 . The most common predisposing factors are IV drug @entity299 . @entity794 is the most common pathogen. The clinical manifestations include @entity221 , chills, rigor, @entity1353 , @entity158 , productive cough, and hemoptysis. The cardiac manifestations can be notably absent early in the course of the disease, with only 20% of @entity1 initially showing a significant murmur on physical examination. Peripheral @entity999 can be seen. Echocardiography is helpful in identifying @entity47 on the tricuspid valve in a significant proportion of @entity1 . The chest radiograph is characteristic, showing features typical of multiple @entity1151 . The radiograph shows multiple, small, fuzzy, patchy, peripherally located densities that can change rapidly on serial films. Complications of right-sided @entity884 include @entity8995 , @entity1997 , progressive @entity712 , and @entity8 . The treatment of right-sided @entity884 includes prolonged therapy, with high doses of IV bactericidal antibiotics. Four weeks of antibiotic therapy is generally required, but newer regimens using combination antibiotic therapy can be successful in sensitive strains of viridans group streptococci and @entity794 . Surgical resection of the tricuspid valve is recommended for organisms that do not respond to initial antibiotic therapy, @entity364 , resistant relapsing organisms, or coexistent infection with @entity794 and @entity796 . The prognosis of right-sided @entity884 is generally favorable when compared with left-sided @entity884 . The prognosis is especially favorable in IV drug abusers infected with @entity794 . @entity1 infected with fungal organisms, @entity796 or @entity34565 , have a worse prognosis. The presence of significant @entity712 also imparts a worse prognosis.

title: XXXX arising from right-sided heart structures.

entities_list: @entity1997 :: ('MESH:D008169', 'Disease') :: ['pulmonary abscess']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['right-sided heart failure']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal abnormalities']

entities_list: @entity796 :: ('287', 'Species') :: ['Pseudomonas', 'P. aeruginosa']

entities_list: @entity8995 :: ('MESH:D054060', 'Disease') :: ['pulmonary infarction']

entities_list: @entity999 :: ('MESH:D020766', 'Disease') :: ['embolic lesions']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['septic pulmonary emboli']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['Endovascular infections', 'deep-seated infection']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal endocarditis']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pleuritic pain']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['abuse and congenital heart disease']

entities_list: @entity47 :: ('MESH:D018458', 'Disease') :: ['vegetations']

entities_list: @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']

entities_list: @entity884 :: ('MESH:D004696', 'Disease') :: ['endocarditis']

answer: @entity281 :: (MESH:D007239,Disease) :: ['Endovascular infections']


abstract: OBJECTIVES: We analyzed the relationship of @entity28 , determined by body mass index (BMI), to short- and long-term outcomes in the TARGET trial. BACKGROUND: : Previous studies have conflicting findings regarding the relationship of BMI to outcomes following percutaneous coronary intervention (PCI). METHODS: The TARGET trial studied the use of glycoprotein (GP) IIb/IIIa inhibition in @entity1 undergoing planned coronary stent placement. RESULTS: Eighty-one percent of all @entity1 were overweight (BMI > 25), 36% were @entity28 (BMI > 30), and United States @entity1 were more frequently @entity28 (38.7% vs. 25.8%, P < 0.001). @entity28 @entity1 had a similar 30-day @entity63 event rate compared with nonobese @entity1 , but less major @entity548 (0.4% vs. 1.1%, P = 0.013). Six-month @entity204 and @entity583 rates were similar in @entity28 and nonobese @entity1 . There was a J-shaped relationship between 6-month target vessel revascularization (TVR) and BMI with the lowest incidence of TVR at BMI 27.5. Six-month TVR was higher in the morbidly (BMI > 35) @entity28 (12.4% vs 8.7%, P < 0.05). In extremely (BMI > 32) @entity28 @entity1 , this relationship was more significant (TVR 11.3% vs. 8.5%, P = 0.007), particularly in @entity1 <65 years of age (TVR 12.3% vs. 8.4%, P = 0.003). CONCLUSION: The majority of @entity1 undergoing PCI are overweight, especially in the United States. Extreme @entity28 is associated with a significant increase in TVR following intent-to-stent PCI, especially in @entity1 <65 years of age. With routine use of @entity1427 /IIIa inhibitors, other long- and short-term @entity63 events are similar in @entity28 and nonobese @entity1 . However, @entity28 @entity1 have significantly less major @entity548 .

title: The relationship of XXXX to @entity63 outcomes following coronary stent placement in contemporary practice.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity', 'obese', 'Obese']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: The purpose of this article is to describe development of a culturally adapted @entity308 intervention (Oh Happy Day Class, OHDC) designed for African American adults experiencing @entity308 ( @entity308 ). This project included 2 pilot studies testing the feasibility and acceptability of the OHDC and examining short-term effects of the OHDC in reducing symptoms of @entity308 . The OHDC is a 2.5-hr weekly, culturally specific, cognitive behavioral, group counseling intervention for 12 weeks. Cultural adaptations of the OHDC are based on the ecological validity and culturally sensitive framework, along with an Afrocentric paradigm. Fifty African American @entity1 with @entity308 were enrolled (15 in Pilot I and 35 in Pilot II). All @entity1 in Pilots I and II received the 12-week intervention and completed assessments at baseline, mid-intervention, end-intervention, and 3 months postintervention. General linear mixed modeling for assessment of pre-post longitudinal data analysis was conducted. Results for Pilot I showed 73% of @entity1 completed the full OHDC, a statistically significant decline in @entity308 symptoms from pre- to postintervention, and a 0.38 effect size. @entity1 were very satisfied with the OHDC. In Pilot II, 66% of @entity1 completed the full OHDC, and there was a significant pre-post intervention decrease in @entity308 symptoms. For @entity1 , the OHDC showed a 1.01 effect size and for @entity1 , a 0.41 effect size. Both @entity1 and @entity1 were very satisfied with the OHDC based on the satisfaction measure. These promising findings are discussed with a focus on future plans for examining efficacy of the OHDC in a large-scale, randomized, control trial. (PsycINFO Database Record (c) 2014 APA, all rights reserved).

title: A Culturally Adapted XXXX Intervention for African American Adults Experiencing @entity308 : Oh Happy Day.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'Participants', 'men']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['MDD', 'depression', 'major depressive disorder']

answer: @entity308 :: (MESH:D003866,Disease) :: ['Depression']


abstract: OBJECTIVE: This study's objective was to quantify the impact (utility) of common complications of early @entity5 treatment on quality of life (QOL). Utilities assigned by survivors were compared to those assigned by providers. METHODS: 30 survivors of early @entity5 identified from our Tumor Registry and 10 gynecologic oncology providers were interviewed. @entity1 evaluated complications (health states) using the standard gamble (SG) and visual analogue scale (VAS). Each @entity1 was randomly assigned to rate 5 of 13 health states. Mixed-effects linear models were used to generate confidence intervals for utility means, and evaluate the effect of group (survivors versus providers). Higher utilities indicate the health state is closer to perfect health. RESULTS: Survivors and providers mean ages were similar (44 and 40). Mean time from diagnosis was 6.7 years. 28 of 30 survivors had no evidence of disease. 56% of survivors had complications. Using SG, providers consistently assigned utilities 7% higher than survivors (p=0.035) for all health states except "ileostomy", which survivors rated higher than providers. Survivors assigned the lowest utility to @entity1744 ( @entity1744 ) (fixable without an ostomy) and @entity1695 ( @entity1695 ). Survivors rated @entity1744 16% and @entity1695 21% lower than providers. Personal history of complications or higher stage did not have a consistent effect on QOL adjustments. DISCUSSION: Providers assign higher utilities than survivors to health states. Providers and survivors diverge on which complications impact QOL the most. Data on @entity1 preferences should be considered when weighing treatment options with similar survival but different associated complications.

title: Quality of life in XXXX survivors: @entity1 and provider perspectives on common complications of @entity5 and treatment.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['participant', 'patient', 'Participants']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['SBO', 'small bowel obstruction']

entities_list: @entity1695 :: ('MESH:D014517', 'Disease') :: ['UO', 'ureteral obstruction']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']